JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CHEN, K. K.
Right arrow Articles by ANDERSON, R. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by CHEN, K. K.
Right arrow Articles by ANDERSON, R. C.
Journal of Pharmacology And Experimental Therapeutics, Vol. 99, Issue 4, 395-400, 1950
Copyright © 1950 by American Society for Pharmacology and Experimental Therapeutics

THE CARDIAC ACTION OF HELLEBORUS GLYCOSIDES AND THEIR AGLYCONES

K. K. CHEN 1, FRANCIS G. HENDERSON 1, and ROBERT C. ANDERSON 1

1 Lilly Research Laboratories, Indianapolis 6, Indiana

1. The potency of hellebrin, hellebrigenin, hellebrigenin monoacetate and hellebrigenol monoacetate has been compared with desgluco-hellebrin in etherized cats. Hellebrin is less active than desgiuco-hellebrin. Unexpectedly the aglycone hellebrigenin is more potent than either hellebrin or desgluco-hellebrin. Hellebrigenin monoacetate is more active than hellebrigenol monoacetate, and it is the most potent cardiac product so far studied.

2. Hellebrin, hellebrigenin and its monoacetate, and hellebrigenol monoacetate, all produce vomiting in pigeons and cats, and cause contractions in smoothmuscle organs.

Submitted on March 29, 1950






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1950 by the American Society for Pharmacology and Experimental Therapeutics.